The Patent Finder

Humanetics Corporation

Also on record
Records under this name other than the patents Humanetics Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.

Back to Humanetics Corporation

PatentTitleStatus Expires Confidence
US 9,623,004Administration of a Therapeutic Amount of Genistein to Mitigate Erectile Dysfunction Resulting from Radiation Therapy for Prostate Cancer Only Throughout a Defined Administration Period Commencing Shortly Before and Concluding After Radiation Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,779,644Sensitizing cells to proton radiation
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,129,894Sensitizing Cells to Proton Radiation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 7,199,116Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal
Formerly held
Term ended
Term ended Sep 26, 2024 · High confidence
Term endedTerm ended Sep 26, 2024High confidence
US 7,109,358Process for the Preparation of Isoflavones
Term ended
Term ended Apr 23, 2023 · High confidence
Term endedTerm ended Apr 23, 2023High confidence
US 7,553,829Treatment of Chronic Fatigue Syndrome and Fibromyalgia Syndrome
Formerly held
Lapsed on the fee record
Ended Jun 30, 2021 · High confidence
Lapsed on the fee recordEnded Jun 30, 2021High confidence
US 6,518,318Stimulating transport of glucose into animal tissue by the administration of pinitol
Term ended
Term ended May 30, 2021 · From the USPTO record
Term endedTerm ended May 30, 2021From the USPTO record
US 6,153,606Memory enhancement by the administration of .DELTA.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof
Formerly held
Term ended
Term ended Oct 16, 2018 · From the USPTO record
Term endedTerm ended Oct 16, 2018From the USPTO record
US 6,489,313Memory by the administration of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and 3&bgr; esters
Formerly held
Term ended
Term ended Oct 16, 2018 · From the USPTO record
Term endedTerm ended Oct 16, 2018From the USPTO record
US 6,593,316Use of DELTA5-ANDROSTENE-3BETA OL-7,17-Dione in the Treatment of Lupus Erythematosus
Formerly held
Lapsed on the fee record
Ended Jul 15, 2011 · Low confidence
Lapsed on the fee recordEnded Jul 15, 2011Low confidence
10 of 39 patents shown.
Pro members see all 39.
Pro members: see all 39 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited